Policy paper

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

MHRA position paper, to help encourage the development and licensing of Microbiome-Based Medicinal Products (MBMPs) products in the UK.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 18 August 2026

Documents

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

HTML

Details

Microbiome-based medicinal products (MBMPs) represent an emerging class of therapeutics with the potential to address areas of significant unmet clinical need. The purpose of this position paper is to encourage the development and licensing of these products in the UK.

Published 18 August 2026